PDS Biotechnology (PDSB) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on PDS Biotechnology (PDSB) is Neutral.

The composite score behind that read is -0.06, weighing +0.07 of bullish evidence against -0.45 bearish.

PDS Biotechnology last closed at $1.38, +35.29% on the session.

Against the IVW growth benchmark the position is +34.49% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

20 graded predictions for PDSB so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks PDS Biotechnology in the 1st percentile on return on equity, where 100 is best.

PDS Biotechnology is classified under Health Care / Biotechnology, with a market capitalisation of $73.92M.

StockMap tracks PDS Biotechnology as the 293rd largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite PDS Biotechnology ranks 170th of 381 in the group, against a group median of -0.08.